ePrints

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide

Lookup NU author(s): Huw ThomasORCiD, Mike Cole, Suzanne Elliott, Professor Herbie Newell, Professor Alan Calvert, Dr Martin Highley, Professor Alan Boddy

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Aims: Cisplatin and carboplatin are often used in combination with etoposide. In a randomized cross-over study, the potential interaction between the two platinum drugs and the metabolism of etoposide was explored. In vitro investigations using human liver microsomes were also performed. Methods: Etoposide was administered to 15 patients over 3 days, with the platinum drug administered on day 2. The alternate platinum drug was administered on the second course. The pharmacokinetics of etoposide were determined on all 3 days of each cycle. The effect of platinum drugs on etoposide metabolism by human liver enzymes was explored in vitro. Results: Neither cisplatin nor carboplatin coadministration affected the pharmacokinetics of etoposide during cycle 1. When carboplatin was administered on course 2, etoposide AUC was 8% higher on day 2 compared with day 1 or day 3 (for day 2 vs day 3, 95% CI: -0.72, -0.08 mg ml-1 min). In contrast, cisplatin on course 2 increased the AUC of etoposide (28%) on day 3 (day 3 vs day 1, 95% CI: 0.67, 2.09 mg ml-1 min), with no effect on day 2. In vitro carboplatin and cisplatin (10-100 μM) inhibited the metabolism of etoposide, if rat liver microsomes were preincubated (30 min) with NADPH and the platinum complexes. With human liver microsomes a small effect on etoposide metabolism, but not on catechol formation, was observed. Conclusions: The interaction between etoposide and platinum drugs is small and, given the pharmacokinetic variability seen with etoposide, the clinical impact is unlikely to be significant.

Publication metadata

Author(s): Thomas HD, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV

Publication type: Article

Publication status: Published

Journal: British Journal of Clinical Pharmacology

Year: 2002

Volume: 53

Issue: 1

Pages: 83-91

Print publication date: 01/01/2002

ISSN (print): 0306-5251

ISSN (electronic): 1365-2125

URL: http://dx.doi.org/10.1046/j.0306-5251.2001.01513.x

DOI: 10.1046/j.0306-5251.2001.01513.x

PubMed id: 11849199

Altmetrics

Share